Alistair Duncan, B.Sc., C.A.
Co-founder of the Company in 2008 Mr. Duncan serves as President and Chief Executive Officer (CEO) of the Company. From 2009 to present, Mr. Duncan was co-founder, Director, and has served as interim Chief Financial Officer for Agrisoma Biosciences Inc., a company building a high performance crop seeds business for the development of new genetically modified crops for renewable fuels. From 1998 to 2008, Mr. Duncan was President and CEO of Chromos Molecular Systems Inc., where he was also a co-founder and Director. Prior to that, he was a Principal with the Ernst & Young Corporate Finance and International Life Sciences Group where he provided high technology and life sciences companies with corporate advisory services in strategic planning, valuations, financing, divestitures, and mergers and acquisitions. Currently, Mr. Duncan also serves as a director on the board of Metro Vancouver Properties Corp. Mr. Duncan is a member of the Institute of Chartered Accountants of British Columbia and holds a B.Sc. in Biochemistry from the University of British Columbia.
David Granville, Ph.D., F.A.H.A.
Co-founder and scientific founder of the Company in 2008, Dr. Granville serves as the Company’s Chief Scientific Officer (CSO) and is a Full Professor and Director of the GEM Facility at the Providence Heart + Lung Institute at St. Paul’s Hospital, University of British Columbia (UBC). Dr. Granville completed his Ph.D. at UBC and post-doctoral training at the Scripps Research Institute (La Jolla, CA). He worked in preclinical pharmacology at QLT Inc. from 1994-2000. Dr. Granville was recruited to UBC in 2003 as a Tier II Canada Research Chair and Michael Smith Foundation for Health Research Scholar. Since then, Dr. Granville has received numerous awards for his scholarly and research achievements including a Canada Top 40 Under 40™ award, 2010 Business in Vancouver Forty Under 40 award, 2006 UBC Outstanding Young Alumnus Award, 2007 Simon Fraser University Academic Alumnus Award, 2008 Canadian Academy of Pathology Scientist award and was a finalist for the prestigious 2007 Louis and Arnold Katz Basic Science Prize at the American Heart Association Scientific Sessions. Dr Granville is a Fellow of the American Heart Association (F.A.H.A.) and Scholar of the Royal Society of Canada.
Jeff Charpentier, C.A.
Mr. Charpentier is a veteran of the biopharmaceutical industry with over 25 years of experience. Jeff has held a series of senior financial roles at several public and private companies in the pharmaceutical and technology sectors where he led multiple equity financings, raising in excess of $150M and concluded a number of corporate partnering/product sale transactions. Jeff previously served as CFO for Lifebank Corp. (through to successful company sale in 2012), Inex Pharmaceuticals Corporation (now Arbutus Biopharma Corp.), and Chromos Molecular Systems Inc. Jeff has a Bachelor of Commerce degree from the University of British Columbia and is a member of the Chartered Professional Accountants of BC.
Beth Allison, Ph.D.
Dr. Allison serves as Director, Drug Development. Her experience spans 20 years in academia, contract research, and biotechnology. Most recently Dr. Allison served as a founder and VP, Scientific and Business Development, at IonsGate Preclinical Services Inc. and as Director, Biology at Cardiome Pharma Corporation. Here she contributed to the development of Vernakalant IV (BrinavessTM) for conversion of recent onset atrial fibrillation to sinus rhythm. Dr. Allison is a lead inventor of Visudyne®, the first drug developed for Age Related Macular Degeneration by QLT Inc. She was involved in the development of this drug at QLT Inc. for five years, from 1997-2002. Previously, Dr. Allison was an Assistant Professor in the Department of Surgery, Division of Vascular Surgery, at UBC. Dr. Allison holds a Ph. D. in Microbiology and Immunology from UBC and a BSc. in Biochemistry from McMaster University.
As Vice President, Business Development, Ms. Morgan leads and facilitates viDA’s corporate partnering efforts. She identifies research collaborations and evaluates licensing opportunities for the development of viDA's technology. Most recently she has worked with several small start-up companies in the life sciences sector, functioning as the Business Development lead, to license key technologies and develop corporate strategy for company positioning and growth through New Perspectives, Inc. Prior to New Perspectives, Ms Morgan held a position with Nektar Therapeutics as Director of Business Development responsible for licensing activities of Nektar’s proprietary products in gastroenterology, pain and oncology therapeutics. Ms. Morgan is a member of the Licensing Executives Society and served on the Advisory Board of Envion International. She received her undergraduate degree in Psychology and an M.B.A. from Miami University, Oxford, Ohio.
Dale Cameron, Ph.D., M.C.I.C
Dr. Cameron serves as Associate Director, Medicinal Chemistry, and nominal Head of Drug Discovery. His professional experience over the past 18 years includes a variety of roles in Computational Chemistry, Medicinal Chemistry and Intellectual Property (IP) at small and large pharmaceutical companies and as a private consultant. From 2009 to 2012 he operated as a consultant to two companies in a variety of roles including computational chemistry, intellectual property, and business development support. Prior to that he served in several roles at local biotech company, MIGENIX (Micrologix Biotech), most recently as Director, Research (Anti-Infectives) and Manager, Intellectual Property (in a concurrent role) and was responsible for Drug Discovery Research activities in antibacterial, anti-viral, and anti-fungal programs. He also managed the IP portfolio and other roles including evaluation of potential licensing opportunities. Prior to this Dr. Cameron spent almost 6 years at Boehringer Ingelheim (Canada) Ltd, in Laval, QC where he most recently served as the Head of Structural Research as a Sr. Research Scientist in Computational Chemistry. In this he was awarded, as part of a team, the 2000 Boehringer Ingelheim R&D Award for his role in the identification of BILN2061, the first Hepatitis C Virus Protease inhibitor to proceed to human clinical trials. He is coauthor on over 30 scientific publications and is named as inventor on at least 12 patent families. He has a Bachelor of Science (Hons., Subject of Specialization) in Chemistry and a Ph.D. in Chemistry both from Queen’s University.